Zacks Research Downgrades West Pharmaceutical Services (NYSE:WST) to Hold

Key Points

• Zacks Research downgraded West Pharmaceutical Services (NYSE:WST) from a "strong-buy" to a hold rating.
• Despite the downgrade, the stock has a consensus of Moderate Buy with an average analyst price target of $315.67, and several firms continue to issue buy ratings and high price targets (e.g., Deutsche Bank $315, Jefferies $295).
• West reported a Q4 earnings beat (EPS $2.04 vs. $1.83; revenue $805M vs. $795.7M), set FY2026 guidance of $7.85–$8.20 EPS, and authorized a $1.00 billion share buyback (up to 5.6% of shares).

West Pharmaceutical Services (NYSE:WST - Get Free Report) was downgraded by investment analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

WST has been the topic of several other research reports. Wall Street Zen raised West Pharmaceutical Services from a "hold" rating to a "buy" rating in a research note on Saturday, December 20th. Jefferies Financial Group reaffirmed a "buy" rating and set a $295.00 price objective on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of West Pharmaceutical Services in a research note on Friday, January 9th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $315.00 price objective on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Finally, Barclays raised their price objective on West Pharmaceutical Services from $265.00 to $275.00 and gave the stock an "equal weight" rating in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $315.67.

West Pharmaceutical Services Stock Performance

WST stock opened at $266.45 on Tuesday. The company has a market cap of $19.21 billion, a P/E ratio of 39.24, a price-to-earnings-growth ratio of 2.85 and a beta of 1.15. West Pharmaceutical Services has a twelve month low of $193.05 and a twelve month high of $322.34. The company has a quick ratio of 2.34, a current ratio of 3.02 and a debt-to-equity ratio of 0.06. The business's fifty day moving average is $247.67 and its 200-day moving average is $261.55.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The medical instruments supplier reported $2.04 EPS for the quarter, topping the consensus estimate of $1.83 by $0.21. The business had revenue of $805.00 million for the quarter, compared to the consensus estimate of $795.70 million. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The firm's revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.82 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. Equities research analysts forecast that West Pharmaceutical Services will post 6.62 EPS for the current year.

West Pharmaceutical Services declared that its board has initiated a share buyback program on Tuesday, February 17th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical instruments supplier to reacquire up to 5.6% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's management believes its shares are undervalued.

Hedge Funds Weigh In On West Pharmaceutical Services

Large investors have recently added to or reduced their stakes in the company. Elyxium Wealth LLC bought a new position in West Pharmaceutical Services during the 4th quarter worth about $25,000. CYBER HORNET ETFs LLC bought a new position in West Pharmaceutical Services during the 2nd quarter worth about $25,000. Bayban bought a new position in shares of West Pharmaceutical Services in the 4th quarter valued at about $27,000. Private Trust Co. NA grew its holdings in shares of West Pharmaceutical Services by 156.4% in the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 61 shares in the last quarter. Finally, DV Equities LLC bought a new position in shares of West Pharmaceutical Services in the 4th quarter valued at about $28,000. Institutional investors own 93.90% of the company's stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.